Quarterly report pursuant to Section 13 or 15(d)

Segments (Details)

Segments (Details) - USD ($)	3 Months Ended		9 Months Ended
Segments (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Segment Reporting Information [Line Items]
Lymphoseek sales revenue	$ 2,952,522	$ 1,101,071	$ 6,751,492	$ 2,773,959
Lymphoseek license revenue	550,000	300,000	883,333	300,000
Grant and other revenue	476,755	848,999	1,320,816	1,002,605
Total revenue	3,979,277	2,250,070	8,955,641	4,076,564
Cost of goods sold, excluding depreciation and amortization	442,094		1,167,141
Research and development expenses, excluding depreciation and amortization	3,900,638		10,169,900
Selling, general and administrative expenses, excluding depreciation and amortization	3,827,393		13,137,061
Depreciation and amortization	132,229		431,368	360,702
Loss from operations	(4,323,077)	(5,362,486)	(15,949,829)	(23,157,087)
Other income (expense), excluding equity in the loss of R-NAV, LLC	(3,721,242)		(8,808,202)
Equity in the loss of R-NAV, LLC	(26,785)	(262,198)	(295,217)	(262,198)
Net loss	(8,071,104)	$ (6,898,896)	(25,053,248)	(28,861,683)
Total assets, net of depreciation and amortization	17,483,457		17,483,457		$ 11,830,308
Payments to Acquire Property, Plant, and Equipment	2,788		30,406	$ 1,111,418
Corporate
Segment Reporting Information [Line Items]
Selling, general and administrative expenses, excluding depreciation and amortization	2,721,844		8,381,910
Depreciation and amortization	115,216		223,870
Loss from operations	(2,837,060)		(8,605,780)
Other income (expense), excluding equity in the loss of R-NAV, LLC	(3,721,242)		(8,808,202)
Equity in the loss of R-NAV, LLC	(26,785)		(295,217)
Net loss	(6,585,087)		(17,709,199)
Payments to Acquire Property, Plant, and Equipment	2,788		4,914
United States
Segment Reporting Information [Line Items]
Lymphoseek sales revenue	2,942,498		6,736,418
Total assets, net of depreciation and amortization	17,042,641		17,042,641
United States \| Corporate
Segment Reporting Information [Line Items]
Total assets, net of depreciation and amortization	13,291,939		13,291,939
International
Segment Reporting Information [Line Items]
Lymphoseek sales revenue	10,024		15,074
Total assets, net of depreciation and amortization	440,816		440,816
International \| Corporate
Segment Reporting Information [Line Items]
Total assets, net of depreciation and amortization	467		467
Diagnostics \| Operating Segments
Segment Reporting Information [Line Items]
Lymphoseek license revenue	550,000		883,333
Grant and other revenue	476,755		1,320,816
Total revenue	3,979,277		8,955,641
Cost of goods sold, excluding depreciation and amortization	442,094		1,167,141
Research and development expenses, excluding depreciation and amortization	3,603,501		9,610,012
Selling, general and administrative expenses, excluding depreciation and amortization	1,063,062		4,634,279
Depreciation and amortization	17,013		207,498
Loss from operations	(1,146,393)		(6,663,289)
Net loss	(1,146,393)		(6,663,289)
Payments to Acquire Property, Plant, and Equipment			25,492
Diagnostics \| United States \| Operating Segments
Segment Reporting Information [Line Items]
Lymphoseek sales revenue	2,942,498		6,736,418
Total assets, net of depreciation and amortization	3,750,702		3,750,702
Diagnostics \| International \| Operating Segments
Segment Reporting Information [Line Items]
Lymphoseek sales revenue	10,024		15,074
Total assets, net of depreciation and amortization	440,349		440,349
Therapeutics \| Operating Segments
Segment Reporting Information [Line Items]
Research and development expenses, excluding depreciation and amortization	297,137		559,888
Selling, general and administrative expenses, excluding depreciation and amortization	42,487		120,872
Loss from operations	(339,624)		(680,760)
Net loss	$ (339,624)		$ (680,760)